Prognostic Value of Immunoscore in Colorectal Carcinomas

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Immunoscore evaluates CD3+ and CD8+ T-cell densities in tumor centers and invasive margins.
• It is recognized as a potential prognostic factor, especially in colorectal cancer.
• Assessing Immunoscore's prognostic value across all colorectal cancer stages is crucial.

Purpose of the Study:

• To evaluate the prognostic significance of Immunoscore in colorectal cancer stages I-IV.
• To correlate Immunoscore with clinical parameters and patient survival.
• To determine if Immunoscore can be reliably used in clinical practice.

Main Methods:

• A retrospective study of 104 colorectal cancer cases (2014-2016).
• Immunohistochemical analysis of CD3 and CD8 densities using tissue microarrays.
• Immunoscore calculation based on established methods, with density classified as low or high using median cutoffs.

Main Results:

• Low Immunoscore was observed in 60.6% of patients.
• Low Immunoscore significantly correlated with worse survival (P < .001).
• High Immunoscore significantly enhanced survival (P < .001), and a correlation with T stage was found (P = .026).
• Multivariate analysis identified Immunoscore (P = .001) and age (P = .035) as independent predictors of survival.

Conclusions:

• Immunoscore demonstrates significant prognostic value in colorectal cancer.
• Its reproducibility supports its potential integration into routine clinical practice.
• Immunoscore can aid in optimizing therapeutic management for colorectal cancer patients.